Cassava Sciences Shares Are Trading Lower After the Company Announced Simufilam Did Not Show a Significant Reduction in Cognitive or Functional Decline Versus Placebo in Patients With Mild-to-moderate Alzheimer's Disease in the ReThink-ALZ Phase 3 Study.
Cassava Sciences Shares Are Trading Lower After the Company Announced Simufilam Did Not Show a Significant Reduction in Cognitive or Functional Decline Versus Placebo in Patients With Mild-to-moderate Alzheimer's Disease in the ReThink-ALZ Phase 3 Study.
Cassava Sciences股票下跌，因公司宣布在ReThink-ALZ第3阶段研究中，Simufilam未显示出在轻度至中度阿尔茨海默病患者中相对安慰剂在认知或功能衰退方面显著降低。
Cassava Sciences Shares Are Trading Lower After the Company Announced Simufilam Did Not Show a Significant Reduction in Cognitive or Functional Decline Versus Placebo in Patients With Mild-to-moderate Alzheimer's Disease in the ReThink-ALZ Phase 3 Study.
木薯科学公司宣布，在Rethink-ALZ 3期研究中，与安慰剂相比，Simufilam没有显示出轻度至中度阿尔茨海默氏病患者的认知或功能下降显著减轻，此后，该公司股价走低。
热门讨论
中概股财报季火热：惊喜盈利能否延续涨势？
1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？
Moomoo News Global
03/04 23:26
中国两会：会议前后股票价格走势的主要要点